title: Expression of matriptase and clinical outcome of human endometrial cancer.
abstract: BACKGROUND
  Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix and in progression of some epithelial cancers. The purpose of the present study was to examine matriptase expression and evaluate its clinicopathological significance in endometrial cancer.
  
  
  METHODS
  Matriptase expression was examined in normal endometrium (n=20), endometrial hyperplasia (n=11) and endometrial cancer (n=65) samples. The distribution of cases that scored positive for each of the biological parameters examined was correlated with matriptase expression status obtained by immunohistochemistry.
  
  
  RESULTS
  Matriptase was found to be significantly overexpressed in endometrial cancer as compared with normal endometrium and endometrial hyperplasia. Interestingly, matriptase expression is associated with stage (p=0.010), grade (p=0.021), depth of myometrial invasion (p=0.004), cervical involvement (p=0.021), lymph node metastasis (p=0.009), LVS involvement (p=0.041) and peritoneal cytology (p=0.045). The high matriptase expression was a significant predictor for poor prognosis when compared with low matriptase expression (Disease-free survival rate; p=0.032, Overall survival rate; p=0.011).
  
  
  CONCLUSIONS
  High matriptase expression in endometrial cancer may be associated with poor prognosis.
authors.affiliation: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medical, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. k-nakamu@cc.okayama-u.ac.jp
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Nakamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hongo
authors.forename: Junichi
authors.initials: J
authors.lastname: Kodama
authors.forename: Fernando
authors.initials: F
authors.lastname: Abarzua
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nasu
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hiramatsu
mesh_terms: D016889:Endometrial Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D012697:Serine Endopeptidases / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D012697:Serine Endopeptidases; C485595:matriptase